Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR

NCT00179829 is registered in ClinicalTrials.gov with Ann & Robert H Lurie Children's Hospital of Chicago as lead sponsor.

NCT NCT00179829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00179829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 1999
Completion date
April 30, 2006
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, leukemia